首页 > 最新文献

Current Gastroenterology Reports最新文献

英文 中文
Integrative Approaches to Managing Gut Health. 管理肠道健康的综合方法。
Q1 Medicine Pub Date : 2024-07-01 Epub Date: 2024-03-12 DOI: 10.1007/s11894-024-00927-7
Marvin M Singh

Purpose of review: To summarize key integrative approaches to managing common gastrointestinal conditions.

Recent findings: Lifestyle interventions like diet, exercise, and stress reduction impact the gut microbiome and gastrointestinal symptoms. Evidence supports mind-body therapies, herbs, certain supplements, and other modalities as complimentary approaches, when appropriate, for common conditions like irritable bowel syndrome or gastroesophageal reflux disease. An integrative approach optimizes both conventional treatments and incorporates lifestyle modifications, complimentary modalities, and the doctor-patient relationship.

综述目的总结治疗常见胃肠疾病的主要综合方法:饮食、运动和减压等生活方式干预会影响肠道微生物群和胃肠道症状。有证据表明,心身疗法、草药、某些补充剂和其他方式在适当时可作为治疗肠易激综合征或胃食管反流病等常见疾病的辅助方法。综合疗法优化了传统治疗方法,并结合了生活方式调整、辅助方法和医患关系。
{"title":"Integrative Approaches to Managing Gut Health.","authors":"Marvin M Singh","doi":"10.1007/s11894-024-00927-7","DOIUrl":"10.1007/s11894-024-00927-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>To summarize key integrative approaches to managing common gastrointestinal conditions.</p><p><strong>Recent findings: </strong>Lifestyle interventions like diet, exercise, and stress reduction impact the gut microbiome and gastrointestinal symptoms. Evidence supports mind-body therapies, herbs, certain supplements, and other modalities as complimentary approaches, when appropriate, for common conditions like irritable bowel syndrome or gastroesophageal reflux disease. An integrative approach optimizes both conventional treatments and incorporates lifestyle modifications, complimentary modalities, and the doctor-patient relationship.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"181-189"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Esophagogastric Junction Outflow Obstruction (EGJOO): A Manometric Phenomenon or Clinically Impactful Problem. 食管胃交界流出道梗阻 (EGJOO):是人体测量现象还是有临床影响的问题?
Q1 Medicine Pub Date : 2024-07-01 Epub Date: 2024-03-28 DOI: 10.1007/s11894-024-00928-6
Laura Bach, Marcelo F Vela

Purpose of review: Esophagogastric junction outflow obstruction (EGJOO), defined manometrically by impaired esophagogastric junction relaxation (EGJ) with preserved peristalsis, can be artifactual, due to secondary etiologies (mechanical, medication-induced), or a true motility disorder. The purpose of this review is to go over the evolving approach to diagnosing and treating clinically relevant EGJOO.

Recent findings: Timed barium esophagram (TBE) and the functional lumen imaging probe (FLIP) are useful to identify clinically relevant EGJOO that merits lower esophageal sphincter (LES) directed therapies. There are no randomized controlled trials evaluating EJGOO treatment. Uncontrolled trials show effectiveness for pneumatic dilation and peroral endoscopic myotomy to treat confirmed EGJOO; Botox and Heller myotomy may also be considered but data for confirmed EGJOO is more limited. Diagnosis of clinically relevant idiopathic EGJOO requires symptoms, exclusion of mechanical and medication-related etiologies, and confirmation of EGJ obstruction by TBE or FLIP. Botox LES injection has limited durability, it can be used in patients who are not candidates for other treatments. PD and POEM are effective in confirmed EGJOO, Heller myotomy may also be considered but data for confirmed EGJOO is limited. Randomized controlled trials are needed to clarify optimal management of EGJOO.

审查目的:食管胃交界处流出道梗阻(EGJOO)是指食管胃交界处松弛功能(EGJ)受损而蠕动功能保持不变,根据压力计定义,这种梗阻可能是人为的,也可能是继发性病因(机械性、药物引起的)或真正的运动障碍。本综述旨在介绍诊断和治疗临床相关 EGJOO 的不断发展的方法:定时食管钡餐造影(TBE)和功能性管腔成像探针(FLIP)有助于识别临床相关的 EGJOO,这些 EGJOO 值得采用下食管括约肌(LES)导向疗法。目前还没有评估 EJGOO 治疗的随机对照试验。非对照试验显示,气压扩张和口腔内窥镜肌切开术对治疗确诊的 EGJOO 有效;肉毒杆菌毒素和海勒肌切开术也可考虑,但用于确诊的 EGJOO 的数据较为有限。诊断临床相关的特发性 EGJOO 需要症状、排除机械和药物相关病因,并通过 TBE 或 FLIP 确认 EGJ 阻塞。肉毒杆菌毒素 LES 注射的持久性有限,但可用于不适合接受其他治疗的患者。PD和POEM对确诊的EGJOO有效,也可考虑进行海勒肌切开术,但确诊的EGJOO数据有限。需要进行随机对照试验,以明确 EGJOO 的最佳治疗方法。
{"title":"Esophagogastric Junction Outflow Obstruction (EGJOO): A Manometric Phenomenon or Clinically Impactful Problem.","authors":"Laura Bach, Marcelo F Vela","doi":"10.1007/s11894-024-00928-6","DOIUrl":"10.1007/s11894-024-00928-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Esophagogastric junction outflow obstruction (EGJOO), defined manometrically by impaired esophagogastric junction relaxation (EGJ) with preserved peristalsis, can be artifactual, due to secondary etiologies (mechanical, medication-induced), or a true motility disorder. The purpose of this review is to go over the evolving approach to diagnosing and treating clinically relevant EGJOO.</p><p><strong>Recent findings: </strong>Timed barium esophagram (TBE) and the functional lumen imaging probe (FLIP) are useful to identify clinically relevant EGJOO that merits lower esophageal sphincter (LES) directed therapies. There are no randomized controlled trials evaluating EJGOO treatment. Uncontrolled trials show effectiveness for pneumatic dilation and peroral endoscopic myotomy to treat confirmed EGJOO; Botox and Heller myotomy may also be considered but data for confirmed EGJOO is more limited. Diagnosis of clinically relevant idiopathic EGJOO requires symptoms, exclusion of mechanical and medication-related etiologies, and confirmation of EGJ obstruction by TBE or FLIP. Botox LES injection has limited durability, it can be used in patients who are not candidates for other treatments. PD and POEM are effective in confirmed EGJOO, Heller myotomy may also be considered but data for confirmed EGJOO is limited. Randomized controlled trials are needed to clarify optimal management of EGJOO.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"173-180"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Ileus Represent the Forgotten End Organ Failure in Critical Illness? 回肠是否代表了危重病中被遗忘的终末器官衰竭?
Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-04-01 DOI: 10.1007/s11894-023-00910-8
Christy M Lawson, Chris Jones, Michael Herman, Cecilia Kim, Elizabeth Mannino, Endashaw Omer, Carlas Venegas

Purpose of review: This review evaluates the current literature on ileus, impaired gastrointestinal transit (IGT), and acute gastrointestinal injury (AGI) and its impact on multiple organ dysfunction syndrome.

Recent findings: Ileus is often under recognized in critically ill patients and is associated with significant morbidity and is potentially a marker of disease severity as seen in other organs like kidneys (ATN).

综述目的:本综述评估了有关回肠、胃肠道转运受损(IGT)和急性胃肠道损伤(AGI)及其对多器官功能障碍综合征影响的现有文献:回肠梗阻在危重病人中往往未得到充分认识,它与严重的发病率有关,并有可能成为肾脏等其他器官(ATN)疾病严重程度的标志。
{"title":"Does Ileus Represent the Forgotten End Organ Failure in Critical Illness?","authors":"Christy M Lawson, Chris Jones, Michael Herman, Cecilia Kim, Elizabeth Mannino, Endashaw Omer, Carlas Venegas","doi":"10.1007/s11894-023-00910-8","DOIUrl":"10.1007/s11894-023-00910-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review evaluates the current literature on ileus, impaired gastrointestinal transit (IGT), and acute gastrointestinal injury (AGI) and its impact on multiple organ dysfunction syndrome.</p><p><strong>Recent findings: </strong>Ileus is often under recognized in critically ill patients and is associated with significant morbidity and is potentially a marker of disease severity as seen in other organs like kidneys (ATN).</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"166-171"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140335058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peri-Operative Optimization of Patients with Crohn's Disease. 克罗恩病患者的围手术期优化。
Q1 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-29 DOI: 10.1007/s11894-024-00925-9
Hareem Syed, Ahmed Nadeem, David Gardinier, Kendra Weekley, Dovid Ribakow, Stephen Lupe, Shubha Bhat, Stefan Holubar, Benjamin L Cohen

Purpose of review: The management of patients with Crohn's disease (CD) undergoing surgery is complex and optimization of modifiable factors perioperatively can improve outcomes. This review focuses on the perioperative management of CD patients undergoing surgery, emphasizing the need for a multi-disciplinary approach.

Recent findings: Research highlights the benefits of a comprehensive strategy, involving nutritional optimization, psychological assessment, and addressing septic complications before surgery. Despite many CD patients being on immune-suppressing medications, studies indicate that most of these medications are safe to use and should not delay surgery. However, a personalized approach for each case is needed. This review underscores the importance of multi-disciplinary team led peri-operative management of CD patients. We suggest that this can be done at a dedicated perioperative clinic for prehabilitation, with the potential to enhance outcomes for CD patients undergoing surgery.

审查目的:对接受外科手术的克罗恩病(CD)患者的管理非常复杂,优化围手术期可改变的因素可改善预后。本综述重点关注接受手术的克罗恩病患者的围手术期管理,强调多学科方法的必要性:研究强调了综合策略的益处,包括营养优化、心理评估以及术前处理败血症并发症。尽管许多 CD 患者正在服用免疫抑制药物,但研究表明,这些药物大多可以安全使用,不应延误手术。然而,每个病例都需要个性化的治疗方法。本综述强调了由多学科团队主导的 CD 患者围手术期管理的重要性。我们建议可以在专门的围手术期诊所进行术前康复治疗,这样有可能提高接受手术的 CD 患者的治疗效果。
{"title":"Peri-Operative Optimization of Patients with Crohn's Disease.","authors":"Hareem Syed, Ahmed Nadeem, David Gardinier, Kendra Weekley, Dovid Ribakow, Stephen Lupe, Shubha Bhat, Stefan Holubar, Benjamin L Cohen","doi":"10.1007/s11894-024-00925-9","DOIUrl":"10.1007/s11894-024-00925-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>The management of patients with Crohn's disease (CD) undergoing surgery is complex and optimization of modifiable factors perioperatively can improve outcomes. This review focuses on the perioperative management of CD patients undergoing surgery, emphasizing the need for a multi-disciplinary approach.</p><p><strong>Recent findings: </strong>Research highlights the benefits of a comprehensive strategy, involving nutritional optimization, psychological assessment, and addressing septic complications before surgery. Despite many CD patients being on immune-suppressing medications, studies indicate that most of these medications are safe to use and should not delay surgery. However, a personalized approach for each case is needed. This review underscores the importance of multi-disciplinary team led peri-operative management of CD patients. We suggest that this can be done at a dedicated perioperative clinic for prehabilitation, with the potential to enhance outcomes for CD patients undergoing surgery.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"125-136"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11081987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence and IBD: Where are We Now and Where Will We Be in the Future? 人工智能与 IBD:我们现在在哪里,未来会在哪里?
Q1 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-27 DOI: 10.1007/s11894-024-00918-8
Mehwish Ahmed, Molly L Stone, Ryan W Stidham

Purpose of review: Artificial intelligence (AI) is quickly demonstrating the ability to address problems and challenges in the care of IBD. This review with commentary will highlight today's advancements in AI applications for IBD in image analysis, understanding text, and replicating clinical knowledge and experience.

Recent findings: Advancements in machine learning methods, availability of high-performance computing, and increasing digitization of medical data are providing opportunities for AI to assist in IBD care. Multiple groups have demonstrated the ability of AI to replicate expert endoscopic scoring in IBD, with expansion into automated capsule endoscopy, enterography, and histologic interpretations. Further, AI image analysis is being used to develop new endoscopic scoring with more granularity and detail than is possible using conventional methods. Advancements in natural language processing are proving to reduce laborious tasks required in the care of IBD, including documentation, information searches, and chart review. Finally, large language models and chatbots that can understand language and generate human-like replies are beginning to exhibit clinical intelligence that will revolutionize how we deliver IBD care. Today, AI is being deployed to replicate expert judgement in specific tasks where disagreement, subjectivity, and bias are common. However, the near future will herald contributions of AI doing what we cannot, including new detailed measures of IBD, enhanced analysis of images, and perhaps even fully automating care. As we speculate on future technologic capabilities that may improve how we care for IBD, this review will also consider how we will implement and fairly use AI in practice.

审查目的:人工智能(AI)正迅速显示出解决 IBD 护理问题和挑战的能力。这篇带评论的综述将重点介绍当今人工智能在IBD图像分析、理解文本以及复制临床知识和经验方面的应用进展:机器学习方法的进步、高性能计算的可用性以及医疗数据的日益数字化,都为人工智能提供了协助 IBD 治疗的机会。多个研究小组已经证明了人工智能复制专家内镜评分的能力,并扩展到自动胶囊内镜检查、肠造影术和组织学解释。此外,人工智能图像分析还被用于开发新的内窥镜评分方法,其颗粒度和细节都比传统方法要高。事实证明,自然语言处理技术的进步减少了 IBD 护理过程中所需的繁重工作,包括文档记录、信息搜索和病历审查。最后,能够理解语言并生成类人回复的大型语言模型和聊天机器人开始展现临床智能,这将彻底改变我们提供 IBD 护理的方式。如今,人工智能正被用于复制专家在特定任务中的判断,在这些任务中,分歧、主观性和偏见很常见。然而,在不久的将来,人工智能将为我们所做不到的事情做出贡献,包括对 IBD 进行新的详细测量、增强图像分析,甚至可能实现护理的完全自动化。当我们推测未来的技术能力可能会改善我们对 IBD 的护理时,本综述也将考虑我们将如何在实践中实施和公平地使用人工智能。
{"title":"Artificial Intelligence and IBD: Where are We Now and Where Will We Be in the Future?","authors":"Mehwish Ahmed, Molly L Stone, Ryan W Stidham","doi":"10.1007/s11894-024-00918-8","DOIUrl":"10.1007/s11894-024-00918-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Artificial intelligence (AI) is quickly demonstrating the ability to address problems and challenges in the care of IBD. This review with commentary will highlight today's advancements in AI applications for IBD in image analysis, understanding text, and replicating clinical knowledge and experience.</p><p><strong>Recent findings: </strong>Advancements in machine learning methods, availability of high-performance computing, and increasing digitization of medical data are providing opportunities for AI to assist in IBD care. Multiple groups have demonstrated the ability of AI to replicate expert endoscopic scoring in IBD, with expansion into automated capsule endoscopy, enterography, and histologic interpretations. Further, AI image analysis is being used to develop new endoscopic scoring with more granularity and detail than is possible using conventional methods. Advancements in natural language processing are proving to reduce laborious tasks required in the care of IBD, including documentation, information searches, and chart review. Finally, large language models and chatbots that can understand language and generate human-like replies are beginning to exhibit clinical intelligence that will revolutionize how we deliver IBD care. Today, AI is being deployed to replicate expert judgement in specific tasks where disagreement, subjectivity, and bias are common. However, the near future will herald contributions of AI doing what we cannot, including new detailed measures of IBD, enhanced analysis of images, and perhaps even fully automating care. As we speculate on future technologic capabilities that may improve how we care for IBD, this review will also consider how we will implement and fairly use AI in practice.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"137-144"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing Risks with Newer Oral Small Molecules in Patients with Inflammatory Bowel Diseases. 管理炎症性肠病患者使用新型口服小分子药物的风险。
Q1 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-14 DOI: 10.1007/s11894-024-00923-x
Malek Ayoub, Shivani Mattay, Andres J Yarur, Parakkal Deepak

Purpose of review: Treatment of Inflammatory Bowel Diseases (IBD) is challenging; thus, the need for newer therapeutic options with an oral route of administration has led to the development of novel small molecules drugs (SMDs). We aim to highlight the most common Adverse events (AEs) associated with SMDs and recommendations on monitoring for AEs before and during treatment.

Recent findings: SMDs, such as Tofacitinib, a JAK inhibitor, have been associated with laboratory abnormalities, infections, and risk of thromboembolic events. Therefore, oral agents with greater selectivity in JAK inhibition, such as tofacitinib and upadacitinib, were later developed. Ozanimod and etrasimod, S1PR agonists, require closer safety profile monitoring by clinicians. Multiple therapies have been recently developed with variable efficacy. However, they have been associated with AEs, and some require close monitoring prior to and during therapy. Clinicians should highlight these adverse events to patients while reassuring the safety profile of these novel SMDs for IBD is favorable.

综述目的:炎症性肠病(IBD)的治疗极具挑战性;因此,由于需要更新的口服给药途径治疗方案,新型小分子药物(SMDs)应运而生。我们旨在强调与小分子药物相关的最常见不良事件(AEs),以及在治疗前和治疗期间监测AEs的建议:最近的研究结果:SMDs(如 JAK 抑制剂托法替尼)与实验室异常、感染和血栓栓塞事件风险有关。因此,后来开发出了对 JAK 抑制具有更大选择性的口服药物,如托法替尼和乌达替尼。S1PR激动剂奥扎莫德(Ozanimod)和依曲莫德(etrasimod)需要临床医生进行更严密的安全性监测。最近开发的多种疗法疗效不一。然而,这些疗法也存在不良反应,其中一些需要在治疗前和治疗期间进行密切监测。临床医生应向患者强调这些不良事件,同时保证这些新型 SMDs 对治疗 IBD 的安全性是有利的。
{"title":"Managing Risks with Newer Oral Small Molecules in Patients with Inflammatory Bowel Diseases.","authors":"Malek Ayoub, Shivani Mattay, Andres J Yarur, Parakkal Deepak","doi":"10.1007/s11894-024-00923-x","DOIUrl":"10.1007/s11894-024-00923-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Treatment of Inflammatory Bowel Diseases (IBD) is challenging; thus, the need for newer therapeutic options with an oral route of administration has led to the development of novel small molecules drugs (SMDs). We aim to highlight the most common Adverse events (AEs) associated with SMDs and recommendations on monitoring for AEs before and during treatment.</p><p><strong>Recent findings: </strong>SMDs, such as Tofacitinib, a JAK inhibitor, have been associated with laboratory abnormalities, infections, and risk of thromboembolic events. Therefore, oral agents with greater selectivity in JAK inhibition, such as tofacitinib and upadacitinib, were later developed. Ozanimod and etrasimod, S1PR agonists, require closer safety profile monitoring by clinicians. Multiple therapies have been recently developed with variable efficacy. However, they have been associated with AEs, and some require close monitoring prior to and during therapy. Clinicians should highlight these adverse events to patients while reassuring the safety profile of these novel SMDs for IBD is favorable.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"145-156"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139729224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of the Gut Microbiome in Health and Disease in the Elderly. 肠道微生物组在老年人健康和疾病中的作用。
Q1 Medicine Pub Date : 2024-04-20 DOI: 10.1007/s11894-024-00932-w
Lea Ann Chen, Kaitlyn Boyle
{"title":"The Role of the Gut Microbiome in Health and Disease in the Elderly.","authors":"Lea Ann Chen, Kaitlyn Boyle","doi":"10.1007/s11894-024-00932-w","DOIUrl":"https://doi.org/10.1007/s11894-024-00932-w","url":null,"abstract":"","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"118 46","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140680587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Capsules for the Diagnosis and Treatment of Gastrointestinal Motility Disorders- A Game Changer. 用于诊断和治疗胃肠道运动障碍的胶囊--游戏规则的改变者。
Q1 Medicine Pub Date : 2024-04-17 DOI: 10.1007/s11894-024-00926-8
Irene Sonu, Sun Jung Oh, Satish S C Rao
{"title":"Capsules for the Diagnosis and Treatment of Gastrointestinal Motility Disorders- A Game Changer.","authors":"Irene Sonu, Sun Jung Oh, Satish S C Rao","doi":"10.1007/s11894-024-00926-8","DOIUrl":"https://doi.org/10.1007/s11894-024-00926-8","url":null,"abstract":"","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":"181 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140693501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GERD after Bariatric Surgery: A Review of the Underlying Causes and Recommendations for Management. 减肥手术后的胃食管反流病:肥胖手术后胃食管反流病:病因综述及治疗建议。
Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2024-02-14 DOI: 10.1007/s11894-024-00919-7
Alison Pletch, Anne Lidor

Purpose of review: GERD after bariatric surgery is an ongoing concern for bariatric surgeons and their patients. This paper reviews the association of persistent or de novo GERD after multiple types of bariatric surgery, and focuses on the work up and management of GERD after SG.

Recent findings: Two recent large, multicenter randomized clinical trials have shown stronger associations between SG and GERD compared to RYGB. A large group of internationally recognized bariatric surgeons collaborated on 72 consensus statements to help guide the bariatric community on the subject of redo surgeries after SG, including as it pertains to GERD. We present an algorithm that consolidates the best-practices recommendations of the work-up and management of GERD after sleeve gastrectomy, and mention areas of persistent controversy where future research is warranted.

审查目的:减肥手术后的胃食管反流一直是减肥外科医生及其患者关注的问题。本文回顾了多种类型减肥手术后持续性或新发胃食管反流病的相关性,并重点讨论了SG术后胃食管反流病的治疗和管理:最近的两项大型多中心随机临床试验显示,与 RYGB 相比,SG 与胃食管反流病之间的关联性更强。一大批国际知名的减肥外科医生合作制定了 72 项共识声明,以帮助指导减肥界关于 SG 术后重做手术(包括与胃食管反流病相关的手术)的讨论。我们提出了一种算法,整合了袖带胃切除术后胃食管反流病的检查和管理的最佳实践建议,并提到了未来需要研究的持续争议领域。
{"title":"GERD after Bariatric Surgery: A Review of the Underlying Causes and Recommendations for Management.","authors":"Alison Pletch, Anne Lidor","doi":"10.1007/s11894-024-00919-7","DOIUrl":"10.1007/s11894-024-00919-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>GERD after bariatric surgery is an ongoing concern for bariatric surgeons and their patients. This paper reviews the association of persistent or de novo GERD after multiple types of bariatric surgery, and focuses on the work up and management of GERD after SG.</p><p><strong>Recent findings: </strong>Two recent large, multicenter randomized clinical trials have shown stronger associations between SG and GERD compared to RYGB. A large group of internationally recognized bariatric surgeons collaborated on 72 consensus statements to help guide the bariatric community on the subject of redo surgeries after SG, including as it pertains to GERD. We present an algorithm that consolidates the best-practices recommendations of the work-up and management of GERD after sleeve gastrectomy, and mention areas of persistent controversy where future research is warranted.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"99-106"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139729223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Non-ablative Radiofrequency Treatment (Stretta) for Gastroesophageal Reflux Disease (GERD). 治疗胃食管反流病(GERD)的内窥镜非烧蚀射频治疗(Stretta)。
Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.1007/s11894-024-00917-9
George Triadafilopoulos

Purpose of review: Gastroesophageal reflux disease (GERD) is very common in the general population and poses a large societal socio-economic burden. In this article, we review the evidence supporting non-ablative radiofrequency treatment (Stretta) for the endoscopic management of GERD and we compare it to pharmacologic and other minimally invasive and surgical interventions.

Recent findings: Proton pump inhibitors (PPI) are a key therapy for GERD. For patients without associated significant sliding hiatal hernia, who have inadequate relief of their reflux symptoms, Stretta and other endoscopic therapies, such as transoral fundoplication (TIF), may improve symptoms and GERD-related quality of life. Unfortunately, there are no recent large randomized controlled trials, and most of the evidence is based on meta-analyses and small scale, prospective and retrospective single center efforts. Comparisons of Stretta efficacy to other anti-reflux endoscopic modalities and anti-reflux surgery (ARS) are also presented. There are several endoscopic and minimally invasive modalities to manage PPI-refractory GERD acting through various mechanisms that have been found effective in managing GERD symptoms and quality of life. Among them, Stretta has the longest track record of efficacy and safety. Larger-scale and longer-term comparative efficacy trials in selected populations of patients with acid reflux with and without hiatal hernia will be needed.

审查目的:胃食管反流病(GERD)在普通人群中非常常见,给社会造成了巨大的社会经济负担。本文回顾了支持非烧蚀射频治疗(Stretta)用于内镜治疗胃食管反流病的证据,并将其与药物及其他微创和手术干预措施进行了比较:质子泵抑制剂(PPI)是治疗胃食管反流病的主要疗法。对于没有伴发明显滑动性食管裂孔疝、反流症状缓解不充分的患者,Stretta 和其他内窥镜疗法(如经口胃底折叠术(TIF))可改善症状和与胃食管反流相关的生活质量。遗憾的是,最近还没有大型随机对照试验,大多数证据都是基于荟萃分析和小规模、前瞻性和回顾性的单中心研究。此外,还介绍了 Stretta 与其他抗反流内镜方法和抗反流手术(ARS)的疗效比较。目前有几种内镜和微创方法可通过不同机制治疗 PPI 难治性胃食管反流病,这些方法在控制胃食管反流病症状和生活质量方面效果显著。其中,Stretta 具有最长的疗效和安全性记录。还需要在选定的伴有或不伴有食管裂孔疝的胃酸倒流患者群体中进行更大规模和更长期的疗效比较试验。
{"title":"Endoscopic Non-ablative Radiofrequency Treatment (Stretta) for Gastroesophageal Reflux Disease (GERD).","authors":"George Triadafilopoulos","doi":"10.1007/s11894-024-00917-9","DOIUrl":"10.1007/s11894-024-00917-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Gastroesophageal reflux disease (GERD) is very common in the general population and poses a large societal socio-economic burden. In this article, we review the evidence supporting non-ablative radiofrequency treatment (Stretta) for the endoscopic management of GERD and we compare it to pharmacologic and other minimally invasive and surgical interventions.</p><p><strong>Recent findings: </strong>Proton pump inhibitors (PPI) are a key therapy for GERD. For patients without associated significant sliding hiatal hernia, who have inadequate relief of their reflux symptoms, Stretta and other endoscopic therapies, such as transoral fundoplication (TIF), may improve symptoms and GERD-related quality of life. Unfortunately, there are no recent large randomized controlled trials, and most of the evidence is based on meta-analyses and small scale, prospective and retrospective single center efforts. Comparisons of Stretta efficacy to other anti-reflux endoscopic modalities and anti-reflux surgery (ARS) are also presented. There are several endoscopic and minimally invasive modalities to manage PPI-refractory GERD acting through various mechanisms that have been found effective in managing GERD symptoms and quality of life. Among them, Stretta has the longest track record of efficacy and safety. Larger-scale and longer-term comparative efficacy trials in selected populations of patients with acid reflux with and without hiatal hernia will be needed.</p>","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Gastroenterology Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1